{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:48:50Z","timestamp":1780451330331,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.clinbiochem.2010.09.029","type":"journal-article","created":{"date-parts":[[2010,10,15]],"date-time":"2010-10-15T04:25:31Z","timestamp":1287116731000},"page":"203-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The serum levels of Receptor Activator of Nuclear Factor-\u03baB Ligand, bone-specific alkaline phosphatase, osteocalcin and osteoprotegerin do not correlate with the radiographically assessed severity of idiopathic hip and knee osteoarthritis"],"prefix":"10.1016","volume":"44","author":[{"given":"Eustathios \u0399.","family":"Kenanidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Potoupnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriakos A.","family":"Papavasiliou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stauros","family":"Pellios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fares E.","family":"Sayegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Petsatodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Karatzas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Kapetanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/B:BGEN.0000025075.04136.ec","article-title":"Soluble receptor activator of nuclear factor-kappaB Ligand (sRANKL)\/OPG balance in ageing and age-associated diseases","volume":"5","author":"Pulsatelli","year":"2004","journal-title":"Biogerontology"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2302\/kjm.58.29","article-title":"New perspective in OA: the OPG and RANKL system as a potential therapeutic target?","volume":"58","author":"Tat","year":"2009","journal-title":"Keio J Med Mar"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0015","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/ageing\/30.5.374","article-title":"The role of bone in OA","volume":"30","author":"Bailey","year":"2009","journal-title":"Age Ageing"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/s101650300001","article-title":"Subchondral bone sclerosis in OA: not just an innocent bystander","volume":"13","author":"Lajeunesse","year":"2003","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0025","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/1529-0131(199805)41:5<891::AID-ART17>3.0.CO;2-X","article-title":"Osteoblast-like cells from human subchondral osteoarthritic bone demonstrate an altered phenotype in vitro: Possible role in subchondral bone sclerosis","volume":"41","author":"Hilal","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0030","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1002\/1529-0131(200112)44:12<2768::AID-ART464>3.0.CO;2-I","article-title":"The OPG\/receptor activator of nuclear factor kappaB\/receptor activator of nuclear factor kappaB ligand system in cartilage","volume":"44","author":"Komuro","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"suppl. II","key":"10.1016\/j.clinbiochem.2010.09.029_bb0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.61.suppl_2.ii32","article-title":"Role of RANKL and RANK in bone loss and arthritis","volume":"61","author":"Jones","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0040","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1146\/annurev.immunol.20.100301.064753","article-title":"RANK-L and RANK: T cells, bone loss, and mammalian evolution","volume":"20","author":"Theill","year":"2002","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00296-004-0579-1","article-title":"OPG and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and OA","volume":"26","author":"Skoumal","year":"2005","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0050","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00774-007-0753-0","article-title":"Expression of bone resorption genes in OA and in osteoporosis","volume":"25","author":"Logar","year":"2007","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0055","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.clinbiochem.2008.02.011","article-title":"High levels of synovial fluid OPG (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee OA","volume":"41","author":"Pilichou","year":"2008","journal-title":"Clin Biochem"},{"issue":"1","key":"10.1016\/j.clinbiochem.2010.09.029_bb0060","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1310\/GTFR-2DRX-M6YE-ELXR","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects (revised October 7, 2000)","volume":"2","author":"World Medical Association General Assembly","year":"2001","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0065","first-page":"197","article-title":"Rheumatism in miners. II. X-ray study","volume":"9","author":"Kellgren","year":"1952","journal-title":"Br J Ind Med"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0070","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1002\/art.23129","article-title":"Can biochemical markers serve as surrogates for imaging in knee OA?","volume":"56","author":"Davis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0075","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/ard.54.4.263","article-title":"Joint space width measures cartilage thickness in OA of the knee: high resolution plain film and double contrast macroradiographic investigation","volume":"54","author":"Buckland-Wright","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0080","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1530\/eje.0.1450681","article-title":"Serum measurement of OPG \u2014 clinical relevance and potential applications","volume":"145","author":"Hofbauer","year":"2001","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0085","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s001980200045","article-title":"Correlates of OPG levels in women and men","volume":"3","author":"Khosla","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0090","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1210\/jc.2005-0794","article-title":"Circulating OPG and receptor activator for nuclear factor kappa B ligand: clinical utility in metabolic bone disease assessment","volume":"90","author":"Rogers","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0095","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0002-9440(10)63560-2","article-title":"Receptor activator of nuclear factor kappa B ligand (RANKL)\/OPG (OPG) ratio is increased in severe osteolysis","volume":"163","author":"Grimaud","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0100","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W","article-title":"Involvement of receptor activator of nuclear factor kappaB ligand\/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis","volume":"43","author":"Takayanagi","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1297-319X(03)00131-3","article-title":"Role for OPG in rheumatoid inflammation","volume":"71","author":"Saidenberg-Kermanac'h","year":"2004","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/meta.2001.19327","article-title":"Relationship between OPG\/osteoclastogenesis inhibitory factor concentration in synovial fluid and disease severity in individuals with OA of the knee","volume":"50","author":"Takemura","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0115","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF03345584","article-title":"Circulating profiles of OPG and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women","volume":"31","author":"Uemura","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0120","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/rheumatology\/keg373","article-title":"Evidence of altered bone turnover, vitamin D and calcium regulation with knee OA in female twins","volume":"42","author":"Hunter","year":"2003","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0125","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00002281-200309000-00020","article-title":"Biomarkers in OA","volume":"15","author":"Garnero","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11926-006-0023-5","article-title":"Use of biochemical markers to study and follow patients with OA","volume":"8","author":"Garnero","year":"2006","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0135","first-page":"444","article-title":"Type-II collagen markers in OA: what do they indicate?","volume":"19","author":"Henrotin","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.clinbiochem.2010.09.029_bb0140","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/art.24184","article-title":"The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in haemophilic arthropathy","volume":"60","author":"Jansen","year":"2009","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991201000456X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991201000456X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:33:33Z","timestamp":1757864013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000991201000456X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":28,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S000991201000456X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2010.09.029","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The serum levels of Receptor Activator of Nuclear Factor-\u03baB Ligand, bone-specific alkaline phosphatase, osteocalcin and osteoprotegerin do not correlate with the radiographically assessed severity of idiopathic hip and knee osteoarthritis","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2010.09.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}